FDA’s Prasad Exits Following Political Backlash Over Sarepta
Vinay Prasad, a senior regulator at the US Food and Drug Administration (FDA), has stepped down from his position following a controversy surrounding his handling of Sarepta Therapeutics Inc.'s gene therapy. The political backlash arose from Prasad's criticism of the FDA's accelerated approval of Sarepta's treatment for a rare genetic disorder. Conservative pundits had accused Prasad of undermining the agency's decision, leading to his departure after a brief tenure at the FDA. The article highlights the tension between regulatory decision-making and political influence, as well as the challenges faced by public officials when their professional judgments are subject to intense scrutiny and criticism from external sources. The incident underscores the delicate balance between scientific integrity and the need to navigate the complex political landscape in the regulatory environment.
Note: This is an AI-generated summary of the original article. For the full story, please visit the source link below.
